Bristol-Myers receives offer from Taisho to purchase UPSA for $1.6B
Bristol-Myers announced that Taisho Pharmaceutical Holdings has offered to purchase Bristol-Myers Squibb's UPSA consumer health business for $1.6B. UPSA develops and delivers important consumer medicines for patients in France, across Europe and additional countries. Taisho is the largest over-the-counter drug company in Japan, with over a century of experience in this field. Taisho holds a leading presence in anti-inflammatory analgesic, cold and flu and hair growth segments in Japan and Southeast Asia. The potential transaction is anticipated to be completed during the first half of 2019, subject to regulatory approvals and satisfaction of certain other customary closing conditions. The offer by Taisho is structured in the form of a "put option" agreement. Under the terms of the agreement, the offer is subject to Bristol-Myers Squibb's exercise of the put option following information and consultation processes with relevant employee representative bodies. Upon exercise of the put option, Bristol-Myers Squibb and Taisho would execute a definitive stock and assets purchase agreement following which Taisho would acquire all of the issued and outstanding shares of capital stock of UPSA SAS, as well as Bristol-Myers Squibb's assets and liabilities relating to the UPSA product portfolio. Assuming completion, Bristol-Myers Squibb estimates the potential transaction would be approximately (4c) dilutive to 2019 earnings.